All In Biotech

Drug Trial Radar · NCT07118891

Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause

A First-in-Human Phase 1/2 Study of ABCL635 in Healthy Participants and in Postmenopausal Women With Moderate-to-Severe Vasomotor Symptoms

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 136 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

136

Planned (sponsor's estimate)

Start

Jun 23, 2025

Primary completion

Feb 2027

Study completion Feb 2027

Sponsor

Lead sponsor
AbCellera Biologics Inc.Industry
Sponsor type
Industry
First posted
Aug 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effects of single and multiple doses of ABCL635 administered by subcutaneous (SC) injection to healthy men and to postmenopausal women with or without any vasomotor symptoms (VMS) or hot flashes, and to postmenopausal women with moderate-to-severe VMS associated with menopause. The safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) parameters of ABCL635 will be assessed in all study participants; the effects on frequency and severity of VMS will be assessed in postmenopausal women who experience moderate-to-severe symptoms.

Conditions

  • Vasomotor Symptoms Associated With Menopause
  • Healthy Volunteers

Interventions

  • ABCL635Biological

    Participants will receive SC administrations of ABCL635

  • PlaceboBiological

    Participants will receive SC administration of placebo (5% dextrose solution)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and severity of adverse events (AE)Time frame: Day 0 to day 197
  2. Number of participants with abnormalities in 12-lead safety electrocardiograms (ECG)Time frame: Day 0 to day 197
  3. Number of participants with abnormalities in physical examinationTime frame: Day 0 to day 197
  4. Number of participants with abnormalities in laboratory parameters, including general biochemistry, hematology, endocrinology, and urinalysisTime frame: Day 0 to day 197

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • CaRe Clinics

    Calgary, Alberta, Canada

  • CaRe Clinics

    Red Deer, Alberta, Canada

  • Mount Saint Joseph Hospital Clinical Trials Phase 1 Unit

    Vancouver, British Columbia, Canada

  • Centricity Research

    Toronto, Ontario, Canada

  • Centricity Research

    Toronto, Ontario, Canada

  • Alpha Recherche Clinique

    Lévis, Quebec, Canada

  • GCP Research

    Montreal, Quebec, Canada

  • Altasciences Company Inc.

    Mount Royal, Quebec, Canada

  • Clinique RSF Inc.

    Québec, Quebec, Canada

  • Diex Recherche Québec

    Québec, Quebec, Canada

  • Diex Recherche Sherbrooke

    Sherbrooke, Quebec, Canada

  • Diex Recherche Trois-Rivières

    Trois-Rivières, Quebec, Canada

  • Diex Recherche Victoriaville

    Victoriaville, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.